Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim drug ‘can reduce limb pain in RLS patients’

Boehringer Ingelheim drug ‘can reduce limb pain in RLS patients’

12th June 2008

Boehringer Ingelheim has announced the publication of new data showing that Mirapexin/Sifrol (pramipexole) can significantly reduce the limb pain in restless leg syndrome (RLS) patients.

The results are from the first study to show the efficacy of the compound in treating limb pain associated with this condition and have been presented at the annual meeting of the Associated Professional Sleep Societies in Baltimore this week.

Boehringer Ingelheim reports that this pain-relieving effect is in addition to the delivery of relief from a broad range of other RLS symptoms, including sleep disruption, mood disturbance and tiredness in the daytime.

Professor Markku Partinen, of the Department of Neurology, at the University of Helsinki, said: “These new findings with pramipexole will be well received by both doctors and patients who are often looking for a fast-acting and effective treatment for the characteristic RLS symptoms, while seeking the added benefit of alleviating the uncomfortable and painful sensations so often associated with RLS.”

He added that prior clinical studies of existing pharmacological agents used to treat limb pain have not shown longer term benefits for this patient group.

In April 2008, Boehringer Ingelheim presented data to the annual meeting of the American Academy of Neurology showing that pramipexole can significantly reduce incidents of sleep disturbance in RLS patients.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.